NBIX Neurocrine Biosciences, Inc. - Common Stock
$154,05
Prix · Aoû 21, 2026
Données fondamentales au Jul 31, 2026
Fourchette 52 semaines
$123–$186
49% of range
Note des analystes
BUY
36 analysts
Objectif de cours
$212
+37% upside
P/E (TTM)
33.0
ROE
16.1%
Marge nette
16.7%
À propos de Neurocrine Biosciences, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Lire la suite
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
NBIX Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$154.05
Capitalisation Boursière
$15.42B
P/E (TTM)
33.0
BPA (TTM)
$4.67
Revenus (TTM)
$2.86B
Rendement div.
—
ROE
16.1%
Dette/Capitaux propres
—
Fourchette 52 semaines
$123 – $186
NBIX Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$2.86B
2016-12-31
→
2025-12-31
BPA
$4.67
2016-12-31
→
2025-12-31
Flux de trésorerie libre
$749M
2016-12-31
→
2025-12-31
Marges
16.7%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
NBIX
Médiane des pairs
P/E (TTM)
33.0
16.9
P/S (TTM)
5.4
9.6
P/B
4.7
7.7
Price / FCF (Cours / FCF)
20.6
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
NBIX
Médiane des pairs
Operating Margin (Marge d'exploitation)
21.6%
—
Net Profit Margin (Marge nette)
16.7%
-36.9%
ROA
11.5%
-21.8%
ROE
16.1%
-47.3%
ROIC
12.9%
—
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
NBIX
Médiane des pairs
Current Ratio (Ratio de liquidité)
3.4
3.5
Quick Ratio (Ratio de liquidité réduite)
1.9
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
NBIX
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
21.4%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
24.3%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
22.3%
—
EPS YoY (BPA Année/Année)
41.9%
—
Net Income YoY (Bénéfice net YoY)
40.2%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
NBIX
Médiane des pairs
NBIX Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
36 analystes
- Achat fort 14 38,9%
- Achat 17 47,2%
- Conserver 5 13,9%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
27 analystes · 2026-08-22
Médiane
$215.00
← En dessous de tous les objectifs
$154.05
Bas
$165.00
Haut
$249.00
Objectif médian
$215.00
+39,6%
Objectif moyen
$211.57
+37,3%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.24%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $1.39 | $1.37 | 0.02% |
| 31 mars 2026 | $1.91 | $1.20 | 0.71% |
| 31 décembre 2025 | $1.91 | $1.20 | 0.71% |
| 30 septembre 2025 | $2.04 | $1.62 | 0.42% |
| 30 juin 2025 | $1.06 | $0.99 | 0.07% |
| 31 mars 2025 | $0.08 | $0.56 | -0.48% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 17
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
Bilan 28
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
Flux de trésorerie 15
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
Liquidité et Solvabilité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
Efficacité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
Taux de croissance 9
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 10
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
Compte de résultat 15
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | -198,600,000 | 99,400,000 | 99,000,000 | 99,700,000 | -201,300,000 | 101,100,000 | 100,800,000 | 99,800,000 | -194,900,000 | 97,900,000 | 97,600,000 | 97,100,000 | -190,900,000 | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | -203,500,000 | 102,500,000 | 101,000,000 | 102,500,000 | -208,100,000 | 104,300,000 | 103,900,000 | 103,600,000 | -197,400,000 | 101,100,000 | 100,200,000 | 97,100,000 | -193,300,000 | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
Bilan 25
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
Flux de trésorerie 12
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
Rentabilité 7
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
Liquidité et Solvabilité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
Efficacité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
Valorisation (TTM) 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.26B | $2.87B | · | $2.68B | $2.47B | $2.30B | · | $2.23B | $2.06B | $1.89B | · | $1.76B | $1.64B | $1.50B | · | $1.37B | |
| Net Income TTM | $659M | $523M | · | $455M | $310M | $246M | · | $321M | $287M | $145M | · | $170M | $70M | $-11M | · | $88M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 26.3 | 25.9 | · | 31.8 | 41.8 | 46.7 | · | 37.0 | 48.8 | 98.5 | · | 67.4 | 140.7 | -723.0 | · | 120.7 | |
| P/S | 5.3 | 4.6 | · | 5.2 | 5.0 | 4.8 | · | 5.2 | 6.8 | 7.4 | · | 6.3 | 5.6 | 6.6 | · | 7.4 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| P / FCF | · | 96.9 | · | · | · | 202.4 | · | · | · | 116.5 | · | · | · | -73.8 | · | · | |
| Earnings Yield | 3.8% | 3.9% | · | 3.1% | 2.4% | 2.1% | · | 2.7% | 2.1% | 1.0% | · | 1.5% | 0.71% | -0.14% | · | 0.83% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Marge d'exploitation % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| Résultat net | $479M | $341M | $250M | $154M | $90M |
| BPA dilué | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| Ratio de liquidité réduite | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $749M | $557M | $362M | $323M | $233M |
Dernières actualités Actualités récentes mentionnant cette entreprise
- Options de décembre 2027 maintenant disponibles pour Neurocrine Biosciences (NBIX)
- Marché boursier aujourd'hui, 6 avril : Soleno Therapeutics grimpe après un accord de rachat tout en espèces de 2,9 milliards de dollars
- Neurocrine va acquérir Soleno pour 2,9 milliards de dollars en espèces ; l'action Soleno bondit avant la bourse
Signaux de trading Signaux d'achat/vente récents avec prix d'entrée et ratio risque/récompense
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 828 déclarants · $10.1B total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 147 (+51 vs T. préc.) | 62 (-36 vs T. préc.) | 305 (+13 vs T. préc.) | 226 (+11 vs T. préc.) | -629K |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| Dodge & Cox | $941 218 594 | 5 584 707 | 9,32% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838 307 078 | 4 974 083 | 8,30% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $766 048 708 | 4 545 339 | 7,58% | Actions |
| STATE STREET CORP | $739 126 759 | 4 385 598 | 7,32% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $393 680 402 | 2 335 897 | 3,90% | Actions |
| TWO SIGMA INVESTMENTS, LP | $349 922 479 | 2 076 260 | 3,46% | Actions |
| Vestal Point Capital, LP | $316 845 800 | 1 880 000 | 3,14% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $294 151 210 | 1 750 392 | 2,91% | Actions |
| RTW INVESTMENTS, LP | $213 689 740 | 1 267 925 | 2,12% | Actions |
| NORGES BANK | $164 132 866 | 973 880 | 1,62% | Actions |
| FIRST TRUST ADVISORS LP | $155 578 851 | 923 125 | 1,54% | Actions |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122 375 286 | 726 112 | 1,21% | Actions |
| TWO SIGMA ADVISERS, LP | $119 504 823 | 842 592 | 1,18% | Actions |
| Swedbank AB | $109 730 107 | 651 082 | 1,09% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $109 170 737 | 647 763 | 1,08% | Actions |
| DIMENSIONAL FUND ADVISORS LP | $109 070 816 | 647 171 | 1,08% | Actions |
| VICTORY CAPITAL MANAGEMENT INC | $104 238 729 | 618 499 | 1,03% | Actions |
| Caisse de depot et placement du Quebec | $91 002 327 | 539 961 | 0,90% | Actions |
| ARMISTICE CAPITAL, LLC | $90 307 457 | 535 838 | 0,89% | Actions |
| PRIMECAP MANAGEMENT CO/CA/ | $82 807 988 | 491 340 | 0,82% | Actions |
| AMERIPRISE FINANCIAL INC | $79 666 260 | 472 708 | 0,79% | Actions |
| Hood River Capital Management LLC | $79 082 184 | 469 233 | 0,78% | Actions |
| ROYAL BANK OF CANADA | $73 348 000 | 435 207 | 0,73% | Actions |
| Pictet Asset Management Holding SA | $72 751 030 | 430 635 | 0,72% | Actions |
| Gotham Asset Management, LLC | $62 622 213 | 371 568 | 0,62% | Actions |
| Fiera Capital Corp | $61 558 083 | 365 254 | 0,61% | Actions |
| BlackRock, Inc. | $61 129 161 | 362 709 | 0,61% | Actions |
| ALLIANCEBERNSTEIN L.P. | $60 767 710 | 461 270 | 0,60% | Actions |
| Vinva Investment Management Ltd | $58 838 530 | 346 109 | 0,58% | Actions |
| AustralianSuper Pty Ltd | $58 817 535 | 348 993 | 0,58% | Actions |
| GOLDMAN SACHS GROUP INC | $58 206 259 | 345 366 | 0,58% | Actions |
| BRAIDWELL LP | $56 656 579 | 336 171 | 0,56% | Actions |
| RHUMBLINE ADVISERS | $52 723 054 | 312 832 | 0,52% | Actions |
| Clearbridge Investments, LLC | $47 391 031 | 281 194 | 0,47% | Actions |
| SEIZERT CAPITAL PARTNERS, LLC | $46 740 991 | 277 337 | 0,46% | Actions |
| Swiss National Bank | $45 319 062 | 268 900 | 0,45% | Actions |
| BARCLAYS PLC | $44 228 304 | 262 428 | 0,44% | Actions |
| ENVESTNET ASSET MANAGEMENT INC | $44 187 600 | 262 192 | 0,44% | Actions |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $44 038 027 | 261 299 | 0,44% | Actions |
| Candriam S.C.A. | $43 932 854 | 260 926 | 0,43% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $43 921 064 | 260 605 | 0,43% | Actions |
| FMR LLC | $40 551 501 | 240 612 | 0,40% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $40 285 595 | 239 034 | 0,40% | Actions |
| California Public Employees Retirement System | $39 090 345 | 231 942 | 0,39% | Actions |
| RENAISSANCE GROUP LLC | $38 589 515 | 228 970 | 0,38% | Actions |
| Assenagon Asset Management S.A. | $37 516 902 | 222 606 | 0,37% | Actions |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $37 508 000 | 222 554 | 0,37% | Actions |
| Sumitomo Mitsui Trust Group, Inc. | $36 317 270 | 215 488 | 0,36% | Actions |
| Carmignac Gestion | $36 083 344 | 214 100 | 0,36% | Actions |
| PFM Health Sciences, LP | $35 966 549 | 213 407 | 0,36% | Actions |
| Bridgewater Associates, LP | $34 663 773 | 205 677 | 0,34% | Actions |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $34 304 966 | 203 548 | 0,34% | Actions |
| Nantahala Capital Management, LLC | $33 707 000 | 200 000 | 0,33% | Option d'achat |
| BANK OF AMERICA CORP /DE/ | $32 143 164 | 190 721 | 0,32% | Actions |
| MORGAN STANLEY | $32 058 612 | 190 219 | 0,32% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31 213 608 | 185 200 | 0,31% | Option de vente |
| FULLER & THALER ASSET MANAGEMENT, INC. | $30 192 001 | 179 149 | 0,30% | Actions |
| PRUDENTIAL FINANCIAL INC | $29 909 064 | 177 465 | 0,30% | Actions |
| SEB Asset Management AB | $29 789 208 | 176 754 | 0,29% | Actions |
| Ensign Peak Advisors, Inc | $29 653 059 | 175 946 | 0,29% | Actions |
| IEQ CAPITAL, LLC | $29 628 432 | 175 800 | 0,29% | Actions |
| MACKENZIE FINANCIAL CORP | $29 609 071 | 175 685 | 0,29% | Actions |
| NEW YORK STATE COMMON RETIREMENT FUND | $29 573 511 | 175 474 | 0,29% | Actions |
| Korea Investment CORP | $29 154 701 | 172 989 | 0,29% | Actions |
| PKO BP BANKOWY Universal Pension Society JSC | $28 786 115 | 170 802 | 0,28% | Actions |
| Zurich Insurance Group Ltd/FI | $28 618 254 | 169 806 | 0,28% | Actions |
| Impax Asset Management Group plc | $26 965 600 | 160 000 | 0,27% | Actions |
| Nearwater Capital Markets, Ltd | $26 122 925 | 155 000 | 0,26% | Actions |
| Mariner, LLC | $25 627 342 | 152 055 | 0,25% | Actions |
| Integral Health Asset Management, LLC | $25 281 000 | 150 000 | 0,25% | Actions |
| Rock Springs Capital Management LP | $24 395 441 | 144 750 | 0,24% | Actions |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $23 738 829 | 140 854 | 0,24% | Actions |
| Fisher Asset Management, LLC | $22 769 751 | 135 104 | 0,23% | Actions |
| Aware Super Pty Ltd as trustee of Aware Super | $22 056 175 | 130 870 | 0,22% | Actions |
| RAYMOND JAMES FINANCIAL INC | $22 009 323 | 130 592 | 0,22% | Actions |
| Hudson Bay Capital Management LP | $21 909 550 | 130 000 | 0,22% | Actions |
| Life Cycle Investment Partners Ltd | $21 287 319 | 126 308 | 0,21% | Actions |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $20 937 370 | 147 623 | 0,21% | Actions |
| DNB Asset Management AS | $20 280 996 | 120 337 | 0,20% | Actions |
| JANE STREET GROUP, LLC | $20 072 518 | 119 100 | 0,20% | Option de vente |
| Sarissa Capital Management LP | $19 639 889 | 116 533 | 0,19% | Actions |
| Andra AP-fonden | $19 522 682 | 148 191 | 0,19% | Actions |
| AMERICAN CENTURY COMPANIES INC | $19 061 140 | 113 099 | 0,19% | Actions |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $18 885 863 | 112 059 | 0,19% | Actions |
| Man Group plc | $18 859 404 | 111 902 | 0,19% | Actions |
| Mitsubishi UFJ Asset Management Co., Ltd. | $18 788 956 | 111 484 | 0,19% | Actions |
| UBS Group AG | $18 243 577 | 108 248 | 0,18% | Actions |
| Robeco Institutional Asset Management B.V. | $18 197 736 | 107 976 | 0,18% | Actions |
| LOOMIS SAYLES & CO L P | $18 108 412 | 107 446 | 0,18% | Actions |
| Retirement Systems of Alabama | $17 527 134 | 103 997 | 0,17% | Actions |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $17 474 389 | 132 643 | 0,17% | Actions |
| ING GROEP NV | $17 224 277 | 102 200 | 0,17% | Actions |
| Legal & General Group Plc | $17 176 748 | 101 918 | 0,17% | Actions |
| RICE HALL JAMES & ASSOCIATES, LLC | $16 886 364 | 100 195 | 0,17% | Actions |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $16 827 572 | 99 912 | 0,17% | Actions |
| CWM, LLC | $16 696 728 | 126 740 | 0,17% | Actions |
| CAPITAL FUND MANAGEMENT S.A. | $16 536 148 | 98 117 | 0,16% | Actions |
| Clark Capital Management Group, Inc. | $15 629 612 | 92 738 | 0,15% | Actions |
| Distillate Capital Partners LLC | $15 604 993 | 92 592 | 0,15% | Actions |
| LAZARD ASSET MANAGEMENT LLC | $15 399 211 | 91 371 | 0,15% | Actions |
Initiés de la société 42 initiés · 21 dirigeants · 15 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 13 février 2025 M | 139 907 | 0 | 0 | $0 |
| Matt Abernethy | Chief Financial Officer | 13 février 2025 M | 35 810 | 0 | 0 | $0 |
| Timothy Coughlin | Chief Financial Officer | 6 février 2017 S | 137 961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 6 février 2017 A | — | 0 | 0 | $0 |
| Ingrid Delaet | Chief Regulatory Officer | 10 juillet 2026 M | 16 225 | 0 | 5 | $-3 747 962 |
| Darin Lippoldt | Chief Legal Officer | 9 juillet 2026 M | 54 729 | 0 | 4 | $-3 497 443 |
| Sanjay Chandru Keswani | Chief Medical Officer | 2 juin 2026 F | 1 479 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 2 juin 2026 M | 22 374 | 0 | 1 | $-2 200 685 |
| David W. Boyer | Chief Corp. Affairs Officer | 13 février 2025 M | 3 565 | 0 | 0 | $0 |
| Eiry Roberts | Chief Medical Officer | 13 février 2025 M | 35 640 | 0 | 0 | $0 |
| Eric Benevich | Chief Commercial Officer | 13 février 2025 M | 44 689 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 8 février 2023 S | 42 337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 31 janvier 2022 A | 82 273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 8 février 2021 A | 157 651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 5 février 2018 A | 55 946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 31 août 2011 A | 118 256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 27 février 2008 A | 9 667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 19 janvier 2006 A | 5 023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 3 juin 2005 A | 11 216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 18 février 2005 A | — | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 18 décembre 2003 S | 7 966 | 0 | 0 | $0 |
| Leslie V Norwalk | Administrateur | 29 juillet 2026 M | 2 430 | 0 | 2 | $-437 584 |
| SHERWIN STEPHEN A | Administrateur | 5 juin 2026 M | 15 860 | 0 | 5 | $-4 132 990 |
| William H Rastetter | Administrateur | 27 mai 2026 A | 43 678 | 0 | 1 | $-2 732 760 |
| Kevin Charles Gorman | Administrateur | 27 mai 2026 A | 511 293 | 0 | 1 | $-37 824 431 |
| Christine A Poon | Administrateur | 27 mai 2026 A | 4 753 | 0 | 0 | $0 |
| POPS RICHARD F | Administrateur | 27 mai 2026 A | 37 798 | 0 | 1 | $-2 364 750 |
| LYONS GARY A | Administrateur | 27 mai 2026 A | 122 141 | 0 | 1 | $-2 289 150 |
| MORROW GEORGE J | Administrateur | 27 mai 2026 A | 10 386 | 0 | 1 | $-2 150 550 |
| Johanna Mercier | Administrateur | 22 mai 2025 M | 3 535 | 0 | 0 | $0 |
| Alfred Sandrock | Administrateur | 22 mai 2019 A | — | 0 | 0 | $0 |
| Corinne H Nevinny | Administrateur | 24 mai 2018 A | 43 283 | 0 | 0 | $0 |
| Thomas W Mitchell | Administrateur | 28 mai 2015 A | 1 000 | 0 | 0 | $0 |
| VALE WYLIE W | Administrateur | 25 mai 2011 A | 231 372 | 0 | 0 | $0 |
| Adrian Adams | Administrateur | 30 juin 2006 A | — | 0 | 0 | $0 |
| NEUROCRINE BIOSCIENCES INC | Détenteur de 10% | 23 février 2023 P | 8 575 316 | 0 | 0 | $0 |
| Jude Onyia | — | 4 août 2026 G | 20 996 | 0 | 1 | $-1 762 710 |
| Shalini Sharp | — | 27 mai 2026 A | 4 088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | — | 22 mai 2017 A | 56 042 | 0 | 0 | $0 |
| HAWRAN PAUL W | — | 18 septembre 2006 J | 132 000 | 0 | 0 | $0 |
| Lawrence Steinman | — | 2 mars 2005 S | 15 500 | 0 | 0 | $0 |
| CONLON PAUL J | — | 16 décembre 2003 S | 57 335 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 1 participation
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 dépôts | 24 février 2023 | — | Dépôt initial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 129 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,43% | 1 793 SH | 20 août 2026 | Quotidien |
| PBE · Invesco Exchange-Traded Fund Trust | 2,26% | 58 850 SH | 20 août 2026 | Quotidien |
| MCOW · Pacer Funds Trust | 2,17% | 162 NS | 30 avril 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 2,01% | 457 NS | 30 avril 2026 | N-PORT |
| SMRI · EA Series Trust | 1,95% | 79 947 NS | 30 avril 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1,89% | 21 868 SH | 20 août 2026 | Quotidien |
| GRPM · Invesco Exchange-Traded Fund Trust | 1,69% | 55 458 SH | 20 août 2026 | Quotidien |
| BUL · Pacer Funds Trust | 1,66% | 16 032 NS | 30 avril 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1,65% | 600 963 SH | 20 août 2026 | Quotidien |
| BBP · ETFis Series Trust I | 1,38% | 6 192 NS | 30 avril 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 1,29% | 23 318 NS | 31 mai 2026 | N-PORT |
| AGNG · Global X Funds | 1,12% | 5 792 NS | 31 mai 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1,12% | 25 480 SH | 20 août 2026 | Quotidien |
| IBB · iShares Trust | 1,05% | 738 646 SH | 20 août 2026 | Quotidien |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,98% | 5 564 SH | 20 août 2026 | Quotidien |
| LABU · Direxion Shares ETF Trust | 0,95% | 37 476 NS | 30 avril 2026 | N-PORT |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 0,93% | 7 516 NS | 30 avril 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,89% | 99 214 SH | 19 août 2026 | Quotidien |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,87% | 57 454 NS | 30 avril 2026 | N-PORT |
| COWG · Pacer Funds Trust | 0,81% | 132 963 NS | 30 avril 2026 | N-PORT |
| BIB · ProShares Trust | 0,80% | 3 712 NS | 31 mai 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,76% | 1 542 NS | 31 mai 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0,76% | 58 135 SH | 20 août 2026 | Quotidien |
| ABOT · Abacus FCF ETF Trust | 0,72% | 240 NS | 30 avril 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,66% | 25 529 NS | 31 mai 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,64% | 136 NS | 29 mai 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,63% | 533 NS | 30 avril 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,55% | 13 166 NS | 30 avril 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,55% | 5 215 NS | 30 avril 2026 | N-PORT |
| ISCG · iShares Trust | 0,49% | 31 640 SH | 20 août 2026 | Quotidien |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,47% | 13 186 SH | 20 août 2026 | Quotidien |
| VBK · VANGUARD INDEX FUNDS | 0,46% | 1 331 820 SH | 19 août 2026 | Quotidien |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,46% | 162 408 SH | 19 août 2026 | Quotidien |
| QLV · FlexShares Trust | 0,46% | 5 915 NS | 30 avril 2026 | N-PORT |
| SDG · iShares Trust | 0,40% | 4 563 SH | 20 août 2026 | Quotidien |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,40% | 15 614 NS | 30 avril 2026 | N-PORT |
| PTMC · Pacer Funds Trust | 0,39% | 11 519 NS | 30 avril 2026 | N-PORT |
| IWP · iShares Trust | 0,37% | 491 893 SH | 20 août 2026 | Quotidien |
| MVV · ProShares Trust | 0,34% | 3 468 NS | 31 mai 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 0,34% | 1 461 NS | 31 mai 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,34% | 16 076 NS | 30 avril 2026 | N-PORT |
| USMV · iShares Trust | 0,34% | 528 728 SH | 20 août 2026 | Quotidien |
| SCHM · SCHWAB STRATEGIC TRUST | 0,29% | 271 303 NS | 31 mai 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,26% | 1 662 NS | 30 avril 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,26% | 40 014 NS | 30 avril 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,25% | 44 691 NS | 30 avril 2026 | N-PORT |
| ISCB · iShares Trust | 0,24% | 4 507 SH | 20 août 2026 | Quotidien |
| UMDD · ProShares Trust | 0,24% | 484 NS | 31 mai 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,24% | 286 599 SH | 19 août 2026 | Quotidien |
| IYH · iShares Trust | 0,23% | 57 675 SH | 20 août 2026 | Quotidien |